HTB: no. 12 – plus HIV and COVID-19 (Dec 2021)

18th International European AIDS Conference (EACS 2021)

EACS case study: how to diagnose HIV on PrEP – stopping PrEP or intensify to ART?

European AIDS Clinical Society honours Simon Collins for longstanding contribution to the field of HIV

The importance of confirming screening test results for diabetes and hypertension

Selected islatravir studies stop enrolment: further complications with important investigational drugs

ECG abnormalities reported by 44% of people older than 40 on ART: results from REPRIEVE study

Rare cases of PML diagnosed at CD4 >200 with undetectable viral load

FDA further limit use of islatravir in ongoing studies

US FDA approves long-acting cabotegravir injections for PrEP: price set at $22,000 a year

56 Dean Street reports M184V common with recent low adherence to PrEP and seven transmissions with good adherence

Reducing the risk of COVID-19 in research that involves interrupting ART

Right to Try: activists challenge a flawed film about a potential HIV cure

New BHIVA statements on HIV and COVID-19 (December 2021)

Myocarditis and pericarditis after COVID-19 vaccines

WHO advises against use of convalescent plasma for COVID-19

HTB: no. 12 – plus HIV and COVID-19 (20 December 2021)

IAS strategy for an HIV cure (2021): easy-to-read Q&A

HTB: no. 11 – plus HIV and COVID-19 (Nov/Dec 2021)

IAS review on HIV cure research: A global scientific strategy to cure HIV (2021)

18th International European AIDS Conference (EACS 2021)

Lenacapavir: drug resistance after viral rebound in treatment experienced participants

Implications of historical M184V on use of dual dolutegravir/lamivudine ART

Stopping long-acting cabotegravir/rilpivirine: 1 in 5 trial participants didn’t restart oral ART within eight weeks

Islatravir plus doravirine dual ART: 144 week follow-up from phase 2 study

HIV-specific mental health services across the EU

NICE approves long-acting cabotegravir and rilpivirine injections in England and Wales

MSD/Merck stop once-weekly NNRTI MK-8507: islatravir studies continue with closer monitoring

UK oral history project for young people who were born with HIV

Colchicine: no clinical benefits against COVID-19 in pooled analysis of RCTs

Eli Lilly withdraw EU application for bNAbs etesevimab and bamlanivimab

HTB: no. 11 – plus HIV and COVID-19 (30 November 2021)

HTB: no. 10 – plus HIV and COVID-19 (31 October 2021)

18th International European AIDS Conference (EACS 2021)

EACS 2021: a call for collaborations and for both HIV and COVID-19 

Reduced responses to COVID-19 vaccines at low CD4 counts

EACS Guidelines: 11th edition (October 2021)

Community “Respect my HIV” march: 30 October 2021 in London

NHS Scotland approves long-acting cabotegravir and rilpivirine injections

Early treatment prevents anal cancer in people living with HIV: ANCHOR study stops early

Benefits reported for continued use of cotrimoxazole prophylaxis at high CD4 counts in Malawi

Gilead withdraws application for F/TAF as PrEP in the EU

BHIVA guidelines for the management of HIV-2 (2021)

Explaining rare cases of HIV remission – and risk of viral rebound after many years off-ART

CHAI 2021 HIV market report: the state of the HIV market in low- and middle-income countries

Continued evidence for poorer COVID-19 outcomes in people with HIV  

Immune responses to natural COVID-19 infection in HIV positive people

Durability of immune responses to COVID-19 vaccines in HIV positive people

Sputnik V vaccine not approved in South Africa due to potential increased risk of HIV

Sanofi reports phase 1/2 mRNA results but withdraws from further COVID19 vaccines

Early efficacy results with oral molnupiravir focuses attention on price and access

HTB: no. 10 – plus HIV and COVID-19 (31 October 2021)

HTB: no. 9 – plus HIV and COVID-19 (17 September 2021)

11th IAS Conference on HIV Science (IAS 2021)

IAS 2021 website now open access

Substudies from the ODYSSEY trial: results July 2021

Trial design for next generation PrEP

Lenacapavir submitted to EMA for MDR HIV

Pipeline report 2021: HIV drugs in development

Darunavir/ritonavir price now US $210 for global access

HPV vaccine prevent penile infections in young gay men

Imbokodo trial results highlight challenge of developing an HIV vaccine and urgent need for access to proven prevention tools

Moderna registers HIV vaccine study

START study: call for participants to attend final visit – please help…

New COVID-19 vaccine information from Modern ART for South Africa

Post navigation